(19)
(11) EP 2 600 879 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.03.2017 Bulletin 2017/10

(45) Mention of the grant of the patent:
07.12.2016 Bulletin 2016/49

(21) Application number: 11745949.5

(22) Date of filing: 05.08.2011
(51) International Patent Classification (IPC): 
A61K 35/74(2015.01)
 A61P 37/04(2006.01)
(86) International application number:
PCT/EP2011/063566
(87) International publication number:
WO 2012/017093 (09.02.2012 Gazette 2012/06)

(54)

BACTERIAL GHOSTS FOR MEDIATING INNATE IMMUNITY

BAKTERIENGHOSTS ZUR VERMITTLUNG ANGEBORENER IMMUNITÄT

HOTES BACTERIENS POUR LA MEDIATION DE L'IMMUNITE INNEE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.08.2010 US 371302 P

(43) Date of publication of application:
12.06.2013 Bulletin 2013/24

(73) Proprietor: BIRD-C GmbH
1030 Wien (AT)

(72) Inventor:
  • LUBITZ, Werner
    3420 Klosterneuburg/Kritzendorf (AT)

(74) Representative: Weickmann & Weickmann PartmbB 
Postfach 860 820
81635 München
81635 München (DE)


(56) References cited: : 
   
  • LUBITZ PETRA ET AL: "Applications of Bacterial Ghosts in Biomedicine", PHARMACEUTICAL BIOTECHNOLOGY SPRINGER-VERLAG BERLIN, HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SERIES : ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY (ISSN 0065-2598(PRINT)), 2009, pages 159-170, XP008145631, cited in the application
  • BÜCHAU AMANDA S ET AL: "S100A15, an antimicrobial protein of the skin: regulation by E. coli through Toll-like receptor 4.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY NOV 2007 LNKD- PUBMED:17625598, vol. 127, no. 11, November 2007 (2007-11), pages 2596-2604, XP002664207, ISSN: 1523-1747
  • FALCHETTI R ET AL: "Effects of resveratrol on human immune cell function.", LIFE SCIENCES 21 NOV 2001 LNKD- PUBMED:11764009, vol. 70, no. 1, 21 November 2001 (2001-11-21), pages 81-96, XP002664208, ISSN: 0024-3205 cited in the application
  • ABTIN A ET AL: "Escherichia coli ghosts promote innate immune responses in human keratinocytes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 2010 ACADEMIC PRESS INC. USA LNKD- DOI:10.1016/J.BBRC.2010.08.013, vol. 400, no. 1, September 2010 (2010-09), pages 78-82, XP27275784, ISSN: 0006-291X
  • A. Abtin ET AL: "Flagellin is the principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human epidermal keratinocytes exposed to Escherichia coli", The FASEB Journal, vol. 22, no. 7, 1 July 2008 (2008-07-01), pages 2168-2176, XP055022093, ISSN: 0892-6638, DOI: 10.1096/fj.07-104117
  • KOLLER VERENA J ET AL: "Modulation of bacterial ghosts - induced nitric oxide production in macrophages by bacterial ghost-delivered resveratrol", FEBS JOURNAL, vol. 280, no. 5, March 2013 (2013-03), pages 1214-1225, ISSN: 1742-464X(print)
  • MADER H J ET AL: "Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines", VACCINE, ELSEVIER LTD, GB, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 195-202, XP004054371, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(96)00141-7
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).